Zenas BioPharma CEO Leon Moulder acquired 60,000 shares of the company for approximately $1.01 million on May 18, 2026. The purchase was made at a weighted average price of $16.88 per share, according to an SEC filing. Following the transaction, Moulder directly holds 423,155 shares, with total beneficial ownership exceeding 520,000 shares, or about 0.95% of outstanding shares, plus an additional 1,786,039 shares held indirectly through Tellus BioVentures LLC. The buy comes after Zenas shares fell from a 52-week high of $44.60 in December 2025, and as the company reported a first-quarter net loss of $81 million, up from $33.6 million a year earlier, with cash and investments of $718.5 million at quarter-end.
Zenas BioPharma, Inc. Common StockCEO insider buying signals confidence in the company's value at current price.